Abstract:Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of coronavirus disease 2019 (Covid-19), an ongoing global public health emergency. Despite the availability of safe and efficacious vaccines, achieving herd immunity remains a challenge due in part to rapid viral evolution. Multiple variants of concern (VOCs) have emerged, the latest being the heavily mutated Omicron, which exhibits the highest resistance to neutralizing antibodies from past vaccination or infection. Currently approved vaccines generate robust systemic immunity, yet poor immunity at the respiratory tract. We have demonstrated that a polymersome-based protein subunit vaccine with wild type (WT) spike protein and CpG adjuvant induces robust systemic immunity (humoral and T cell responses) in mice. Both antigen and adjuvant are encapsulated in artificial cell membrane (ACM) polymersomes – synthetic, nanoscale vesicles that substantially enhance the immune response through efficient delivery to dendritic cells. In the present study, we have formulated a vaccine candidate with the spike protein from Beta variant and assessed its immunogenicity in golden Syrian hamsters. Two doses of ACM-Beta spike vaccine administered via intramuscular (IM) injection evoke modest serum neutralizing titers that are equally efficacious towards WT and Beta viruses. In contrast, the ACM-WT spike vaccine induces a predominantly WT-specific serum neutralizing response with pronounced reduction in potency towards the Beta variant. Remarkably, immunogenicity of the ACM-Beta spike vaccine is greatly enhanced through intranasal (IN) administration. Following IN challenge with the Beta variant, IM-immunized hamsters are fully protected from disease but not infection, displaying similar peak viral RNA loads in oral swabs as non-vaccinated controls. In contrast, hamsters IN vaccinated with ACM-Beta spike vaccine are protected from disease and infection, exhibiting a ∼100-fold drop in total and subgenomic RNA load as early as day 2 post challenge. We further demonstrate that nasal washes from IN-but not IM-immunized animals possess virus neutralizing activity that is broadly efficacious towards Delta and Omicron variants. Altogether, our results show IN administration of ACM-Beta spike vaccine to evoke systemic and mucosal antibodies that cross-neutralize multiple SARS-CoV-2 VOCs. Our work supports IN administration of ACM-Beta spike vaccine for a next-generation vaccination strategy that not only protects against disease but also an infection of the respiratory tract, thus potentially preventing asymptomatic transmission.

Next-Generation SARS-CoV-2 Vaccine Formulations and Alternative Routes of Administration

Adenoviral-vectored next-generation respiratory mucosal vaccines against COVID-19

SARS-CoV-2 Vaccines: The Advantage of Mucosal Vaccine Delivery and Local Immunity

Development of Next-Generation COVID-19 Vaccines: BARDA Supported Phase 2b Study Designs

A Next-Generation Adenoviral Vaccine Elicits Mucosal and Systemic Immunogenicity and Reduces Viral Shedding after SARS-CoV-2 Challenge in Nonhuman Primates

Next-generation intranasal Covid-19 vaccine: a polymersome-based protein subunit formulation that provides robust protection against multiple variants of concern and early reduction in viral load of the upper airway in the golden Syrian hamster model

Vaccine delivery systems and administration routes: Advanced biotechnological techniques to improve the immunization efficacy

Advances in intranasal vaccine delivery: A promising non-invasive route of immunization

Current status of mucosal vaccines against SARS-CoV2: a hope for protective immunity

Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2

Novel Administration Routes, Delivery Vectors, and Application of Vaccines Based on Biotechnologies: A Review

An Intranasal Vaccine Based on Outer Membrane Vesicles Against SARS-CoV-2

An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection

Mucosal Vaccine Development for Respiratory Viral Infections

The development of DNA vaccines against SARS-CoV-2

Mucoadhesive Vaccine Delivery Systems for the Oral Mucosa

Cutting-edge research frontiers in oral cavity vaccines for respiratory diseases: a roadmap for scientific advancement

Next-generation COVID-19 Vaccines: Opportunities for Vaccine Development and Challenges in Tackling COVID-19

Buccal and Sublingual Vaccines: A Review on Oral Mucosal Immunization and Delivery Systems

Next‐Generation Vaccines: Nanoparticle‐Mediated DNA and mRNA Delivery

A systems approach to designing next generation vaccines: combining α-galactose modified antigens with nanoparticle platforms